TY - JOUR
T1 - Multicenter Retrospective Analysis of Chemotherapy for Advanced Pancreatic Acinar Cell Carcinoma
T2 - Potential Efficacy of Platinum-and Irinotecan-Containing Regimens
AU - Takahashi, Hideaki
AU - Ikeda, Masafumi
AU - Shiba, Satoshi
AU - Imaoka, Hiroshi
AU - Todaka, Akiko
AU - Shioji, Kazuhiko
AU - Yane, Kei
AU - Kojima, Yasushi
AU - Kobayashi, Satoshi
AU - Asagi, Akinori
AU - Ozaka, Masato
AU - Takada, Ryoji
AU - Nagashio, Yoshikuni
AU - Horiguchi, Shigeru
AU - Kasuga, Akiyoshi
AU - Suzuki, Eiichiro
AU - Terashima, Takeshi
AU - Ueno, Makoto
AU - Morizane, Chigusa
AU - Furuse, Junji
N1 - Funding Information:
Objectives: The aim of this multicenter retrospective study was to identify the optimal chemotherapeutic regimen for advanced pancreatic acinar cell carcinoma (PACC). Methods: Fifty-eight patients with histopathologically confirmed advanced PACC who had received chemotherapy between 1996 and 2013 were enrolled. The clinical characteristics of the patients and the treatment efficacy data were collected from the medical records at 16 Japanese institutions, using standardized data collection instrument. Results: The most commonly selected treatment regimens were gemcitabine-, fluoropyrimidine-, platinum-, and irinotecan-containing regimens. The over-all response rate in the patients who received first-line chemotherapy were 7% and 38%, respectively, and the median overall survival was 13.2 months. When the data for all the treatment lines were aggregated, the response rates to gemcitabine-, fluoropyrimidine-, platinum-, and irinotecan-containing regimens were 7%, 18%, 40%, and 29%, respectively. The overall survival tended to be better in patients who had received a platinum-containing regimen (hazard ratio, 0.50; 95% confidence interval, 0.23–1.11; P = 0.08) or irinotecan-containing regimen (hazard ratio, 0.42; 95% confidence interval, From the *Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa; †Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo; ‡Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya; §Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka; ||Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata; ¶Center for Gastroenterology, Teine-Keijinkai Hospital, Sapporo; #Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo; **Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama; ††Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama; ‡‡Department of Gastroenterology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo; §§Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka; ||||Department of Hepato-Biliary-Pancreatology, National Kyushu Cancer Center, Fukuoka; ¶¶Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Okayama; ##Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo; ***Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba; and †††Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan. Received for publication June 7, 2020; accepted November 2, 2020. Address correspondence to: Masafumi Ikeda, MD, PhD, Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan (e‐mail: masikeda@east.ncc.go.jp). H.T. and M.I. contributed equally to the study and publication. M.I. ORCID: 0000-0002-4050-2086 This work was supported in part by the National Cancer Center Research and Development Fund (23-A-30, 29-A-3). M.I. has a board membership of Nihon Servier, Novartis, Bayer, Eisai, Eli Lilly, Chugai, AstraZeneca, Shire, Nano Carrier, and ASLAN, grants from Yakult, Ono, Bristol-Myers Squibb, Nano Carrier, Novartis, Bayer, Eisai, Eli Lilly, 0.15–1.19; P = 0.09) at least once in the treatment course as compared with those who had not. Conclusions: Our findings suggested that platinum-and irinotecan-containing regimens exhibited some potential efficacy in patients with advanced PACC.
Funding Information:
MSD, Chugai, AstraZeneca, J-Pharma, Pfizer, ASLAN, Merck Serono, and Takeda, payment for lectures from Taiho, Yakult, Nihon Servier, Novartis, Bayer, Eisai, Eli Lilly, Dainippon Sumitomo, MSD, Mylan, Chugai, Astellas, EA pharma, Gilead, Otsuka, and Teijin. Y.K. has a payment for lectures from Taiho, Chugai, Sanofi, Bristol-Myers Squibb, and Eli Lilly. Expert Testimony from AstraZeneca, grants from Ono, Nano Carrier, BeiGene, Taiho, and Takeda. S.K. has a payment for lectures from Bayer, Boston Scientific, Daiichi Sankyo, Eisai, Kyowa Hakko Kirin, Taiho, and Teijin. M.O. has grants from Astellas, Ono, Taiho, MSD, Incyte and Yakult, payment for lectures from Taiho, Yakult, and Novartis. A.K. has a Consulting fee from Taiho. M.U. has a grants from Astellas, Taiho, Daiichi Sankyo, Eisai, AstraZeneca, Ono, MSD, Merck Serono, Dainippon Sumitomo, Incyte, ASLAN and Yakult, payment for lectures from Taiho, Yakult, AstraZeneca, Teijin, Merck Serono, Nipro, MSD, and Daiichi Sankyo. C.M. has a grants from Yakult, Eisai, Taiho, Merck biopharma, AstraZeneca and J-Phama, payment for lectures from MSD, Yakult, Novartis, Teijin, Taiho and AbbVie. J.F. has a Consultancy of Fujifilm, Ono, Yakult, MSD, Merck Bio, J-Pharma, MSD, Chugai, Taiho, Nihon Servier, AstraZeneca, AbbVie, and Astellas, grants from Ono, MSD, Sumitomo Dainippon, J-Pharma, Yakult, AstraZeneca, Daiichi Sankyo, Eisai, Bayer, Pfizer, Nano Carrier, Kyowa Hakko Kirin, Taiho, Chugai, Sanofi, Takeda, Mochida, Astellas, and Eli Lilly Japan, payment for lectures from Eisai, Bayer, Taiho, Ono, Novartis, Yakult, Teijin, Shionogi, EA pharma, Eli Lilly Japan, Takeda, Chugai, Mochida, Nihon Servier, Sanofi, Fujifilm Toyama, Nobel pharma, Pfizer, Sawai, Daiichi Sankyo, Sumitomo Dainippon, Merck Serono, Nippon Kayaku, MSD, Shire, and Kyowa Hakko Kirin. The other authors declare no conflict of interest.
PY - 2021
Y1 - 2021
N2 - Objectives The aim of this multicenter retrospective study was to identify the optimal chemotherapeutic regimen for advanced pancreatic acinar cell carcinoma (PACC). Methods Fifty-eight patients with histopathologically confirmed advanced PACC who had received chemotherapy between 1996 and 2013 were enrolled. The clinical characteristics of the patients and the treatment efficacy data were collected from the medical records at 16 Japanese institutions, using standardized data collection instrument. Results The most commonly selected treatment regimens were gemcitabine-, fluoropyrimidine-, platinum-, and irinotecan-containing regimens. The overall response rate in the patients who received first-line chemotherapy were 7% and 38%, respectively, and the median overall survival was 13.2 months. When the data for all the treatment lines were aggregated, the response rates to gemcitabine-, fluoropyrimidine-, platinum-, and irinotecan-containing regimens were 7%, 18%, 40%, and 29%, respectively. The overall survival tended to be better in patients who had received a platinum-containing regimen (hazard ratio, 0.50; 95% confidence interval, 0.23-1.11; P = 0.08) or irinotecan-containing regimen (hazard ratio, 0.42; 95% confidence interval, 0.15-1.19; P = 0.09) at least once in the treatment course as compared with those who had not. Conclusions Our findings suggested that platinum-and irinotecan-containing regimens exhibited some potential efficacy in patients with advanced PACC.
AB - Objectives The aim of this multicenter retrospective study was to identify the optimal chemotherapeutic regimen for advanced pancreatic acinar cell carcinoma (PACC). Methods Fifty-eight patients with histopathologically confirmed advanced PACC who had received chemotherapy between 1996 and 2013 were enrolled. The clinical characteristics of the patients and the treatment efficacy data were collected from the medical records at 16 Japanese institutions, using standardized data collection instrument. Results The most commonly selected treatment regimens were gemcitabine-, fluoropyrimidine-, platinum-, and irinotecan-containing regimens. The overall response rate in the patients who received first-line chemotherapy were 7% and 38%, respectively, and the median overall survival was 13.2 months. When the data for all the treatment lines were aggregated, the response rates to gemcitabine-, fluoropyrimidine-, platinum-, and irinotecan-containing regimens were 7%, 18%, 40%, and 29%, respectively. The overall survival tended to be better in patients who had received a platinum-containing regimen (hazard ratio, 0.50; 95% confidence interval, 0.23-1.11; P = 0.08) or irinotecan-containing regimen (hazard ratio, 0.42; 95% confidence interval, 0.15-1.19; P = 0.09) at least once in the treatment course as compared with those who had not. Conclusions Our findings suggested that platinum-and irinotecan-containing regimens exhibited some potential efficacy in patients with advanced PACC.
KW - 5-fluorouracil
KW - acinar cell carcinoma
KW - chemotherapy
KW - irinotecan
KW - pancreatic neoplasms
KW - platinum
UR - http://www.scopus.com/inward/record.url?scp=85098154160&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098154160&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000001718
DO - 10.1097/MPA.0000000000001718
M3 - Article
C2 - 33370026
AN - SCOPUS:85098154160
VL - 50
SP - 77
EP - 82
JO - Pancreas
JF - Pancreas
SN - 0885-3177
IS - 1
ER -
